This is the news archive of Facts are Facts.
You can find our recent articles in the section Latest.
It seems quality tests have again discovered sterility problems for Chiron, this time in Germany.
Expected manufacturing of the Bergrivac vaccine has been reduced by some two-thirds (from 12 million to 4 million doses), disabling Chiron from supplying the vaccine to Germany and the United Kingdom for the coming flu season.
The dilemma raises concerns regarding whether the company will be able to resolve its manufacturing tribulations in time to provide the United States with the flu vaccine it needs. Food and Drug Administration (FDA) scientists are currently in the midst of conducting an inspection that will determine if Chiron will be allowed to sell its flu vaccine in the United States this fall.
Though aside from Chiron, the United States has a few flu vaccine providers up its sleeve: